24 Aug Break Dengue Article: Ennaid Therapeutics Potential dengue treatment on the horizon
Researchers hope that understanding the ‘mechanism of action’ of a well-established HIV treatment could lead to the development of a future dengue cure – easing the burden on millions.
Dengue treatment is often limited to hydration and pain control with symptoms normally last from 2-7 days. But, the impact of the disease can last a lot longer. For families affected by dengue, the financial impact alone can be unbearable. According to the International Federation of the Red Cross, the family’s main provider can lose up to 19 days’ work – and wages – by being incapacitated themselves or caring for sick relatives.
But the family’s income is lost when they need it more than ever. On average, 45 percent of dengue treatment costs are borne by the patient’s family and these can be triple the family’s normal monthly income.
The costs of dengue are not completely understood in many dengue-endemic countries which continue to struggle with the economic burden.
Minimizing the impact of this disease on the world’s most vulnerable communities is one of the top priorities for biopharmaceutical company Ennaid Therapeutics. The company is developing nine novel anti-viral drugs – including one for treating dengue.
Sorry, the comment form is closed at this time.